| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/20/2005 | CA2531208A1 Novel immune booster compound comprising an ef adenoviral sequence |
| 01/20/2005 | CA2531161A1 Use of a novel eimeria gene and corresponding protein |
| 01/20/2005 | CA2531118A1 Multivalent carriers of bi-specific antibodies |
| 01/20/2005 | CA2530980A1 Tissue factor-specific antibodies for preventing or treating acute lung injury or acute respiratory distress syndrome |
| 01/20/2005 | CA2530967A1 Inhibition of stress-induced ligand-dependent egfr activation |
| 01/20/2005 | CA2530062A1 Hcv vaccines |
| 01/20/2005 | CA2527102A1 Packaged virus-like particles |
| 01/20/2005 | CA2526402A1 Blys antagonists and uses thereof |
| 01/20/2005 | CA2524853A1 Method of enhanced immunogenicity to meningococcal vaccination |
| 01/19/2005 | EP1498491A1 METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO Fc GAMMA RECEPTOR IIIa |
| 01/19/2005 | EP1498490A1 Process for producing antibody composition |
| 01/19/2005 | EP1498479A2 Non-myeloablative tolerogenic treatment |
| 01/19/2005 | EP1498429A2 Rationally designed antibodies |
| 01/19/2005 | EP1498427A1 Immunoglobulins devoid of light chains |
| 01/19/2005 | EP1498426A1 Preparation of fully human antibodies |
| 01/19/2005 | EP1498415A1 Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs |
| 01/19/2005 | EP1498146A2 In vivo assay and molecular markers for testing the phenotypic stability. |
| 01/19/2005 | EP1498136A2 Non-myeloablative tolerogenic treatment |
| 01/19/2005 | EP1497659A2 An ephrin-b receptor protein involved in carcinoma |
| 01/19/2005 | EP1497658A2 Protein involved in cancer |
| 01/19/2005 | EP1497656A2 Diagnosis of carcinoma using raig1 polypeptides |
| 01/19/2005 | EP1497654A2 Immunoglobulin e vaccines and methods of use thereof |
| 01/19/2005 | EP1497649A2 Antibodies specific for mucin polypeptide |
| 01/19/2005 | EP1497470A2 Methods of identifying compounds that modulate a dna repair pathway and/or retroviral infectivity, the compounds, and uses thereof |
| 01/19/2005 | EP1497467A2 Oligonucleotides from sequences coding for the surface component of ptlv envelope proteins and uses thereof |
| 01/19/2005 | EP1497466A2 Binary or polynary targeting and uses thereof |
| 01/19/2005 | EP1497461A2 Methods of assaying for cell cycle modulators |
| 01/19/2005 | EP1497442A2 Biologic modulations with nanoparticles |
| 01/19/2005 | EP1497425A2 Method of increasing the contractility of a heart, a heart muscle or cells of a heart muscle |
| 01/19/2005 | EP1497417A2 Epha2 antigen t epitopes |
| 01/19/2005 | EP1497414A1 Rapid generation of activated mononuclear antigen presenting cells from monocytes |
| 01/19/2005 | EP1497412A2 Adenovirus vectors for immunotherapy |
| 01/19/2005 | EP1497332A1 Bispecific antibody binding tcr and tirc7 and its use in therapy and diagnosis |
| 01/19/2005 | EP1497330A2 Antagonists of factor viii interaction with low-density lipoprotein receptor-related protein |
| 01/19/2005 | EP1497324A2 CD4 sp + /sp T-LYMPHOCYTE-SPECIFIC HEPATITIS C VIRUS EPITOPES |
| 01/19/2005 | EP1497321A1 Immunological methods and compositions for the treatment of alzheimer's disease |
| 01/19/2005 | EP1497320A2 New gene expressed in prostate cancer and methods of use |
| 01/19/2005 | EP1497315A2 Nucleic acid-associated proteins |
| 01/19/2005 | EP1497313A2 Immunogenic peptide composition for the prevention and treatment of alzheimer's disease |
| 01/19/2005 | EP1497307A2 Recombinant p.falciparum merozoite protein-1 42 vaccine |
| 01/19/2005 | EP1496945A1 Mycoplasma polypeptides |
| 01/19/2005 | EP1496942A1 Microparticles comprising carbohydrate beads covalently linked with allergen |
| 01/19/2005 | EP1496939A2 Modified cea nucleic acid and expression vectors |
| 01/19/2005 | EP1496938A2 Particle-bound human immunodeficiency virus envelope glycoproteins and related compositions and methods |
| 01/19/2005 | EP1496937A2 Dna vaccine combined with an inducer of tumor cell apoptosis |
| 01/19/2005 | EP1496934A2 Adjuvant enhanced immunotherapy |
| 01/19/2005 | EP1496932A2 Anti-hiv composition, production method thereof and medicament |
| 01/19/2005 | EP1496923A1 Cancer immunotherapy |
| 01/19/2005 | EP1496907A2 Tyrosine kinase inhibitors |
| 01/19/2005 | EP1496901A2 Compositions comprising mmp7 modulators for the treatment of chronic pain |
| 01/19/2005 | EP1496897A1 Tyrosine kinase inhibitors |
| 01/19/2005 | EP1496835A2 Compositions and methods for systemic inhibition of cartilage degradation |
| 01/19/2005 | EP1496834A2 High affinity integrin polypeptides and uses thereof |
| 01/19/2005 | EP1496743A2 Compositions and methods for the therapy and diagnosis of lung cancer |
| 01/19/2005 | EP1496742A1 Use of non-antibacterial tetracycline analogs and formulations thereof for the treatment of bacterial exotoxins |
| 01/19/2005 | EP0831779B2 Process for making liposome preparation |
| 01/19/2005 | CN1568331A Biological products |
| 01/19/2005 | CN1568329A Immunogenic peptide composition for the prevention and treatment of Alzheimer's disease |
| 01/19/2005 | CN1568198A Use of cd23 antagonists for the treatment of neoplastic disorders |
| 01/19/2005 | CN1568197A Composite superimmunogen for bi-functional vaccine use for the treatment of illnesses associated with a stromal tissue disorder |
| 01/19/2005 | CN1568194A Modulation of smooth muscle cell proliferation |
| 01/19/2005 | CN1568193A Use of il-18 inhibitors in hypersensitivity disorders |
| 01/19/2005 | CN1566335A Mass preparation of SARS virus capable of meeting the production of inactivated vaccine and inactivation method |
| 01/19/2005 | CN1566334A Novel reovirus, its antibody and vaccine and use thereof |
| 01/19/2005 | CN1566325A Method for making 0157ú‘H7 Enterohemorrhagic Escherichia Coli(EHEC) variation strain |
| 01/19/2005 | CN1566155A Anti-SARS monoclonal antibody, encoding sequence and application thereof |
| 01/19/2005 | CN1566145A Polyvalent pneumococcal polysaccharide combination vaccine |
| 01/19/2005 | CN1566144A Functional protein in SARS coronavirus |
| 01/19/2005 | CN1566114A Novel psoralen derivative for annihilating live virus or germ |
| 01/19/2005 | CN1565631A Usage of fused protein of TNF receptor and globin in acute lung injury treating medicine |
| 01/19/2005 | CN1565630A Novel pestilence DNA vaccine and its construction and application |
| 01/19/2005 | CN1565629A Novel pestilence DNA vaccine and its usage |
| 01/19/2005 | CN1565628A Usage of reovirus genome and its coding protein in the SARS related research |
| 01/19/2005 | CN1565627A Hemoglobin alpha chain peptide fragments useful for inhibiting stem cell proliferation |
| 01/19/2005 | CN1565479A Musk liposome injection and its preparation method |
| 01/19/2005 | CN1185343C New growth-differentiation factor of the TGF-beta family |
| 01/19/2005 | CN1185255C Compositions and Methods for detecting treponema pallidum |
| 01/19/2005 | CN1185253C Neoglycoproteins |
| 01/19/2005 | CN1185012C DNA vaccine pVFS of SARS virus |
| 01/19/2005 | CN1185011C DNA vaccine pVPS of SARS virus |
| 01/19/2005 | CN1184961C Use of EGF-R antagonists in preparing drug |
| 01/18/2005 | USRE38688 Sheet-like diagnostic device |
| 01/18/2005 | US6844422 Inhibitor protein of the wnt signal pathway |
| 01/18/2005 | US6844349 Salt forms of E-2-methoxy-N-(3-{4-[3 methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide and method of production |
| 01/18/2005 | US6844325 Compositions for the treatment and diagnosis of breast cancer and methods for their use |
| 01/18/2005 | US6844314 Use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy |
| 01/18/2005 | US6844189 Chromosome 17P-linked prostate cancer susceptibility gene |
| 01/18/2005 | US6844188 Comprises infectious venezuelan equine encephalitis (VEE) replicon particles for use as gene transfer and theraeutic tools in treatment tumors; anticarcinogenic/antitumor agents; genetic vaccines |
| 01/18/2005 | US6844153 Compositions and methods for identifying and targeting cancer cells of alimentary canal origin |
| 01/18/2005 | US6844014 Corn starch, zinc oxide, carboxymethylcellulose, colostrum, methylparaben, propylparaben, calendula, hypericum, aloe, glycerine, vitamin E and deionized water; relieving skin inflammation and sensitivity; nonantibiotic, nonsteroidal |
| 01/18/2005 | US6844011 Methods for inhibiting rejection of transplanted tissue |
| 01/18/2005 | US6844010 Forming burst free, sustained, programmable release micro-capsules; dissolving active material and blend of glycolide-lactide polymers in methylene chloride; converting to water-oil-water emulsion; removing solvent and lyophilizing |
| 01/18/2005 | US6844009 Media in the form of complex dispersions, method for preparing same and uses |
| 01/18/2005 | US6844001 Adjuvants and copolymer compositions |
| 01/18/2005 | US6844000 A purified Parapoxvirus ovis envelope protein termed "B2L" can be used as a monotherapeutic agent. B2L protein also can be used in screening methods to identify potential therapeutic agents for modulating a subject's immune response |
| 01/18/2005 | US6843999 Streptococcal ABC transporter protein |
| 01/18/2005 | US6843997 Variant varicella-zoster viruses and methods of use |
| 01/18/2005 | US6843996 Immunogenic composition comprising an influenza virus with a temperature sensitive PB2 mutation |
| 01/18/2005 | US6843992 Immuno-reactive peptide CTL epitopes of human cytomegalovirus |
| 01/18/2005 | US6843989 Administering a CD40 binding protein that potentiates the binding of CD40 to CD40 ligand |